Related Experiment Video

Updated: Mar 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date

José Fernando Vilela-Martin1

  • 1Internal Medicine Department, São José do Rio Preto State Medical School (FAMERP), São José do Rio Preto, Brazil.

Drug Design, Development and Therapy
|June 9, 2016
PubMed

Insights

New heart failure drug LCZ696, combining neprilysin inhibition and angiotensin receptor blockade, significantly reduces mortality in patients with reduced ejection fraction heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Translational Medicine

Background:

  • Heart failure with reduced ejection fraction (HFrEF) presents a significant global health challenge with high morbidity and mortality.
  • Pharmacological treatment of HFrEF remains complex, necessitating novel therapeutic strategies.
  • Neprilysin inhibition has been explored for cardiovascular diseases, but faced challenges with efficacy and side effects.

Purpose of the Study:

  • To review pharmacological advancements in HFrEF treatment.
  • To highlight the dual-acting inhibition of neprilysin and the renin-angiotensin-aldosterone system.
  • To emphasize the novel drug LCZ696 for HFrEF management.

Main Methods:

  • Review of pharmacological developments in HFrEF.
  • Focus on drugs targeting neprilysin and the renin-angiotensin-aldosterone system.
  • Analysis of the PARADIGM-HF trial data for LCZ696.

Main Results:

  • LCZ696, a combination of sacubitril (neprilysin inhibitor prodrug) and valsartan (angiotensin receptor blocker), demonstrated superior efficacy.
  • The PARADIGM-HF trial showed LCZ696 reduced mortality compared to enalapril in HFrEF patients.
  • LCZ696 offers a unique mechanism by blocking angiotensin receptors and enhancing natriuretic peptides.

Conclusions:

  • LCZ696 represents a significant pharmacological breakthrough in HFrEF treatment.
  • Dual inhibition of neprilysin and angiotensin receptor blockade offers a novel therapeutic approach.
  • This drug enhances the endogenous natriuretic peptide system, providing a distinct advantage in cardiovascular disease management.

Keywords:
heart failurenatriuretic peptidesneprilysinsacubitrilvalsartanvasopeptidase

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.1K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.2K